Core Viewpoint - A federal judge has ruled that the FDA's determination regarding the shortage of Eli Lilly's drug tirzepatide has ended, and the pharmaceutical company is prohibited from continuing to produce generic versions of the weight loss medication [1] Summary by Relevant Sections - **FDA's Decision**: The FDA legally removed tirzepatide from the shortage list last year, which the court has upheld [1] - **Court Ruling**: Judge Mark T. Pittman of the Northern District of Texas approved the FDA's motion for summary judgment, affirming the agency's position [1] - **Court Records**: The opinion from the court is currently sealed but will eventually be unsealed [1]